Cargando…

Antitumor Efficacy of Hypothemycin, A New Ras‐signaling Inhibitor

We have devised a new drug screening assay to discover anti‐cancer drugs which inhibit Ras‐mediated cellular signals, by utilizing a Ras‐responsive element (RRE)‐driven reporter gene system. We found that hypothemycin, an anti‐bacterial, reduces RRE‐dependent transcription. Treatment of tumor cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Hidekazu, Nishida, Kazuyo, Sugita, Kenji, Yoshioka, Takayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1999
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926000/ https://www.ncbi.nlm.nih.gov/pubmed/10595743 http://dx.doi.org/10.1111/j.1349-7006.1999.tb00688.x

Ejemplares similares

Correction: Hypothemycin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei
por: Nishino, Mari, et al.
Publicado: (2013)

Improved in vivo Antitumor Efficacy and Reduced Systemic Toxicity of Carboxymethylpullulan‐peptide‐doxorubicin Conjugates
por: Nogusa, Hideo, et al.
Publicado: (2000)

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
por: Yuan, Xi, et al.
Publicado: (2020)

Preclinical in vivo Antitumor Efficacy of Nedaplatin with Gemcitabine against Human Lung Cancer
por: Matsumoto, Mitsunobu, et al.
Publicado: (2001)

Dynamic regulation of RAS and RAS signaling
por: Kolch, Walter, et al.
Publicado: (2023)

A new chemical inhibitor of angiogenesis and tumorigenesis that targets the VEGF signaling pathway upstream of Ras
por: Desroches-Castan, Agnès, et al.
Publicado: (2015)

CD59-Regulated Ras Compartmentalization Orchestrates Antitumor T-cell Immunity
por: Li, Luying, et al.
Publicado: (2022)

EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity
por: Berg, Johannes Lorenz, et al.
Publicado: (2021)

Regulation of the Ras-Related Signaling Pathway by Small Molecules Containing an Indole Core Scaffold: A Potential Antitumor Therapy
por: Chen, Fei-Yu, et al.
Publicado: (2020)

Antitumor drug sends new signals
por: Bashyam, Hema
Publicado: (2007)

Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds
por: Cruz-Migoni, Abimael, et al.
Publicado: (2019)

RAS variant signalling
por: Mo, Stephanie P., et al.
Publicado: (2018)

Small Molecule APY606 Displays Extensive Antitumor Activity in Pancreatic Cancer via Impairing Ras-MAPK Signaling
por: Guo, Na, et al.
Publicado: (2016)

Circadian clock-controlled diurnal oscillation of Ras/ERK signaling in mouse liver
por: TSUCHIYA, Yoshiki, et al.
Publicado: (2013)

Mechanisms of Ras Membrane Organization and Signaling: Ras Rocks Again
por: Abankwa, Daniel, et al.
Publicado: (2020)

Ras–ERK Signaling in Behavior: Old Questions and New Perspectives
por: Fasano, Stefania, et al.
Publicado: (2011)

KSR induces RAS‐independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors
por: Paniagua, Guillem, et al.
Publicado: (2022)

An Orthosteric Inhibitor of the Ras-Sos Interaction
por: Patgiri, Anupam, et al.
Publicado: (2011)

RAS MAPK inhibitors deregulation in leukemia
por: Pasmant, Eric, et al.
Publicado: (2015)

Graded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domains
por: Augsten, Martin, et al.
Publicado: (2014)

Regulation of the RAS signaling network
por: Maruta, Hiroshi, et al.
Publicado: (1996)

Compartmentalized Ras signaling in lymphocytes
por: Philips, MR
Publicado: (2009)

Ras signalling in pathogenic yeasts
por: Pentland, Daniel R., et al.
Publicado: (2017)

Regulation of Ras Signaling by S-Nitrosylation
por: Simão, Sónia, et al.
Publicado: (2023)

A computationally engineered RAS rheostat reveals RAS/ERK signaling dynamics
por: Rose, John C., et al.
Publicado: (2016)

Aurora kinase A interacts with H-Ras and potentiates Ras-MAPK signaling
por: Umstead, MaKendra, et al.
Publicado: (2017)

The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β-catenin signaling axis
por: Valverde, Araceli, et al.
Publicado: (2017)

The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling
por: Cui, Yan, et al.
Publicado: (2019)

Impairment of K‐Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR‐143
por: Akao, Yukihiro, et al.
Publicado: (2018)

Avicin G is a potent sphingomyelinase inhibitor and blocks oncogenic K- and H-Ras signaling
por: Garrido, Christian M., et al.
Publicado: (2020)

Anthraquinones as Inhibitors of SOS RAS-GEF Activity
por: Fernández-Medarde, Alberto, et al.
Publicado: (2021)

A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies
por: Manna, Lorenzo, et al.
Publicado: (2023)

Synergistic effects of autophagy/mitophagy inhibitors and magnolol promote apoptosis and antitumor efficacy
por: Tang, Yancheng, et al.
Publicado: (2021)

Thioredoxin Reductase Inhibitors as Potential Antitumors: Mercury Compounds Efficacy in Glioma Cells
por: Pires, Vanessa, et al.
Publicado: (2022)

Ras signaling in aging and metabolic regulation
por: Slack, Cathy
Publicado: (2017)

Localized RAS signaling drives cancer
por: Basu, Sandip K., et al.
Publicado: (2019)

Role of RAS signaling in ovarian cancer
por: Therachiyil, Lubna, et al.
Publicado: (2022)

The novel antitumor compound clinopodiside A induces cytotoxicity via autophagy mediated by the signaling of BLK and RasGRP2 in T24 bladder cancer cells
por: Zhou, Rong Sheng, et al.
Publicado: (2022)

RasGRP3, a Ras activator, contributes to signaling and the tumorigenic phenotype in human melanoma
por: Yang, Dazhi, et al.
Publicado: (2011)

Stabilization of the RAS:PDE6D Complex Is a Novel Strategy to Inhibit RAS Signaling
por: Yelland, Tamas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_195ktu2bl4gpe1jch5tiusft2u